Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Dalpiciclib + Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
NCT05759572Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in breast cancer (2 cohorts), sponsored by Fudan University. Primary endpoint: Progression-Free Survival. Started Mar 2023; status: active, not recruiting.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05759572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759572.